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Abstract
PURPOSE—Li-Fraumeni Syndrome (LFS) is a rare hereditary cancer syndrome associated with
germline mutations in the TP53 gene. While sarcomas, brain tumors, leukemias, breast and
adrenal cortical carcinomas are typically recognized as LFS- associated tumors, the occurrence of
gastrointestinal neoplasms has not been fully evaluated. In this analysis, we investigated the
frequency and characteristics of gastric cancer (GC) in LFS.
METHODS—Pedigrees and medical records of 62 TP53 mutation-positive families were
retrospectively reviewed from the Dana-Farber/National Cancer Institute LFS registry. We
identified subjects with GC documented either by pathology report or death certificate, and
performed pathology review of the available specimens.
RESULTS—Among 62 TP53 mutation-positive families, there were 429 cancer-affected
individuals. GC was the diagnosis in the lineages of 21 (4.9%) subjects from 14 families (22.6%).
The mean and median ages at GC diagnosis were 43 and 36 years, respectively (range 24-74
years), significantly younger compared to the median age at diagnosis in the general population
based on SEER data (71 years). Five (8.1%) families reported 2 or more cases of GC and 6 (9.7%)
families had cases of both colorectal and gastric cancers. No association was seen between
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tphenotype and type/location of the TP53 mutations. Pathology review of the available tumors
revealed both intestinal and diffuse histologies.
CONCLUSIONS—Early-onset GC appears to be a component of LFS, suggesting the need for
early and regular endoscopic screening in individuals with germline TP53 mutations, particularly
among those with a family history of GC.
Keywords
Li Fraumeni syndrome; gastric cancer; hereditary gastric cancer syndromes; germline mutations;
TP53
INTRODUCTION
Gastric cancer is one of the most common cancers worldwide and a leading cause of cancer-
related mortality. In 2010, it is estimated that 21,000 new cases of gastric cancer were
diagnosed in the United States alone and approximately 50% of affected individuals died
from the disease1. Although the majority of gastric cancers are sporadic, about 10% are
familial2, 3. Among the latter group, germline mutations in the CDH1 gene account for
30-40% of the rare syndrome known as Hereditary Diffuse Gastric Cancers (HDGC)4-8.
Gastric cancers also occur, but less frequently, as a component of other hereditary cancer
syndromes (Table 1).
Li-Fraumeni Syndrome (LFS) is a rare autosomal dominant hereditary cancer syndrome
associated with germline mutations in the TP53 tumor suppressor gene9. Sarcomas of soft
tissue and bone, brain tumors, leukemias, breast and adrenal cortical carcinomas are
classically included in the LFS tumor spectrum10, 11. Additional studies have shown that
individuals with germline TP53 mutations have an increased risk of a broad range of
neoplasms, including carcinomas of the lung, gonadal germ cell tumors, melanomas and
lymphomas12-20.
Our group has previously shown that the prevalence of early-onset (age <50 years)
colorectal cancer is increased in LFS families21. This finding led to the inclusion of
surveillance colonoscopy as part of the management approach in TP53 mutation carriers in
the National Comprehensive Cancer Network (NCCN) guidelines22.
As the occurrence of gastric cancer in TP53 mutation carriers has not been well documented,
we searched the LFS family registry of the Dana-Farber Cancer Institute and National
Cancer Institute to assess the number of cases and ages at diagnosis of gastric cancer in
individuals and families with classic LFS or LFS-like histories and germline TP53
mutations. In cases with gastric cancer, we examined whether there were any genotype-
phenotype associations, and performed central pathological review of available tumor
specimens.
MATERIALS AND METHODS
Subject Selection
Subjects were from families previously enrolled in the Dana-Farber Cancer Institute/
National Cancer Institute (DFCI/NCI) LFS family registry. This registry was originally
assembled by Drs. Li and Fraumeni in 1969: new families have been added via self or
physician referral. The registry includes families who meet the classic LFS9 and Li-
Fraumeni-like (LFL) Syndrome criteria23, with or without identified TP53 gene mutations.
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tThe registry is maintained under a clinical protocol reviewed and approved annually by the
Dana Farber/Harvard Cancer Center Institutional Review Board.
The analysis was limited to families with identified pathogenic TP53 mutations. Each
pedigree was reviewed to assign the lineage that was the likely source (maternal or paternal)
of the TP53 mutation. Pedigrees and available medical record data were reviewed to provide
the number, age at diagnosis and histologic features of gastric cancers in the affected lineage
of these families, and to evaluate the occurrence of other gastrointestinal tumors. We then
looked at the different types of TP53 mutations to explore potential genotype/phenotype
correlations. The age range, mean and median ages of diagnosis for the gastrointestinal
tumors were calculated. We used Wilcoxon Rank Sum test to compare the median age at
diagnosis of gastric cancer in our cohort to the corresponding age of gastric cancer in the
general population using data from the Surveillance Epidemiology and End Results (SEER)
database from 2001-200524.
Pathology Review
Pathology information was retrieved from medical records and death certificates, and tumor
specimens were collected for all available cases of gastric cancers from the registry. In
addition, gastric cancer specimens from documented TP53 mutation positive LFS kindreds
were provided by our Brazilian collaborators. These cases from Brazil were included only in
the pathology review, but not in the frequency analysis of GC. Histological review was
performed by a single gastrointestinal pathologist (GYL).
The location of the tumors, histologic type based on the Lauren classification25, and stage
were determined along with the presence of any precursor lesions, such as gastric dysplasia,
intestinal metaplasia, and chronic active gastritis related to Helicobacter pylori infection.
RESULTS
Among 312 families reported in the LFS registry, 62 had confirmed pathogenic TP53
mutations. A total of 429 individuals in the affected lineage of the 62 families had been
diagnosed with one or more cancers. Gastric or gastro-esophageal junction cancers (here
considered as gastric cancer) were diagnosed in 21 (4.9%) individuals from 14 families
(Table 2). Nine gastric cancers (42.9%) were confirmed either by medical and pathological
records or by death certificates while the remaining 12 cases were reported by family
history. Overall, the mean and the median ages at diagnosis of gastric cancer were 43 years
and 36 years, respectively (range 24-74 years). The mean and median ages at diagnosis of
the 9 confirmed cases of gastric cancer were 46 and 36 years, respectively (range 24-74
years), including 5 subjects with gastric cancer before age 40. Twelve of the 21 (57.1%)
cases of gastric cancer in LFS families were diagnosed before age 45 years, with 4 subjects
diagnosed before age 30 (the youngest, 24 years). Of note, the individual with documented
gastric cancer at 74 years of age was a confirmed mutation carrier. The median age at
diagnosis of gastric cancer in this group was significantly younger (p<0.0001) compared to
the SEER dataset (Figure 1).
Thirty-two (51.6%) of the 62 families had at least one family member with gastrointestinal
cancer, including gastric, esophageal, colorectal or pancreatic cancers. There were 14
(22.6%) families with one or more cases of gastric cancer, 5 families (8.1%) with two or
more cases of gastric cancer, and 6 (9.6%) families with cases of both gastric and colorectal
cancers. In examining the pedigrees of the 62 families for additional gastrointestinal tumors
occurring in the affected lineage, we found 28 (4.8%) colorectal cancers (median age at
diagnosis of 53.0 years) and 7 (1.2%) pancreatic cancers (median age of 60.5 years).
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tOverall, 17 (27.4%) of 62 families had cases of gastric or colorectal cancer diagnosed before
age 50 years.
Details of TP53 mutation type were available for all families with gastric cancer cases. Two
families (families 4 and 11 shown in figure 2) had the same mutation in exon 6 (Arg213X).
However, the other 12 families had 12 different mutations distributed along exons 4 to 10
with no clear genotype-phenotype correlation (Table 2).
Characteristics of gastric tumors
Histologic material was available for 5 of the 9 confirmed cases of gastric cancer in the
DFCI/NCI registry and the two additional cases obtained from Brazil (Table 4). Four of the
7 tumors arose in the proximal region of the stomach, two in the antrum, and one in the
fundus; all were advanced at the time of diagnosis. Five of the cases had an intestinal
morphotype (3 moderately differentiated and 2 well differentiated) while two had the diffuse
type with signet ring cells (Figure 3). Two of the tumors were diagnosed at stage pT2, four
at stage pT3 and one at stage pT4. Of note, one of the cases from Brazil was a 12 year old
who had metastatic gastric cancer at presentation.
Gastric dysplasia was not identified in any of the histopathologic material available for
review. Very focal intestinal metaplasia was noted in a single case, while two cases had
features suggestive of Helicobacter pylori inflammation. Although stains for this organism
had not been performed, one case had prominent lymphoid hyperplasia and another had
chronic active gastritis in the surrounding mucosa.
DISCUSSION
In our series of 62 families with TP53 mutations in the DFCI/NCI LFS family registry, 14
(22.6%) families had at least one member diagnosed with gastric cancer. Of 429 family
members with cancer, 21 had gastric cancer (4.9%). Similar to other hereditary cancer
syndromes, the age at diagnosis of gastric cancer in LFS was much younger than in the
general population in the United States (median age at diagnosis at 36 years versus 71 years,
p<0.0001). Although the tumors specimens available for review were limited in number and
amount of tissue, both intestinal and diffuse type gastric cancers were seen, with 50% of the
tumors located in the proximal stomach.
Although literature surveys indicate that gastric cancer is an uncommon manifestation of
LFS 26-29, its occurrence has featured a remarkably young age at diagnosis. In 2001, Nichols
et al reported that among 738 cancer-affected TP53 mutation carriers and their first-degree
relatives from the original DFCI/NIH LFS registry and from the review of the literature
through 1999, there were 23 (3.1%) cases of carcinoma of the stomach17. The International
Agency for Research on Cancer (IARC) TP53 Mutation Database30 compiles all kindreds
with TP53 mutations reported in the published literature since 1989 (DFCI/NCI families are
not included). Among 899 tumors reported in individuals with TP53 germline mutations,
only 16 (1.8%) are gastric tumors. Based on case reports of LFS or LFS-like families
associated with TP53 mutations in Japan and Korea, gastric cancer in LFS seems more
prevalent in Asian populations with high rates of gastric cancer31-35. This finding suggests
that individuals with germline TP53 mutation are susceptible to the carcinogenesis effects of
Helicobacter pylori infection in endemic areas. The interaction may be analogous to the
smoking-related lung cancer and the radiation-related sarcomas reported in LFS. These
studies also suggest that TP53 mutations may be informative in families with early onset
gastric cancer, especially when more characteristic LFS-related tumors are present in the
families. Of note, sporadic TP53 mutations can be found in almost every tumor with a
prevalence of sporadic mutations in stomach cancer of 20%36.
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has limitations based on its retrospective nature, incomplete and missing data, and inability
to confirm the cancer diagnoses and genotypes for all subjects. Although gastric cancers on
average were diagnosed at much younger ages than the SEER population, some of the
tumors occurred at ages above 50 years. As not all individuals with gastric cancer had
mutation testing, some of the cancers at older ages may have represented sporadic cases.
Furthermore, there is always a risk of misclassification associated with abdominal tumors,
since the site of origin may be difficult to discern, even at surgery37. These factors may have
contributed to an overestimate of TP53 mutations associated with gastrointestinal tumors.
To minimize these errors, we carefully reviewed each pedigree and excluded gastric cancers
that were either on the unaffected side of the family or were distant from the proband with
the pathogenic TP53 mutation. We also attempted to confirm as many gastric cancer
diagnoses as possible. Previous studies evaluating the completeness and accuracy of family
history reporting of cancers have found satisfactory reporting of gastrointestinal and intra-
abdominal tumors by family members38, 39. In addition, the majority (81%) of gastric cancer
cases in our study were either probands or first- and second-degree relatives of mutation
carriers. Prior studies have reported that the degree of closeness to an affected relative
correlates with the accuracy of cancer reporting, which is highest for tumors among first-
degree relatives37-39.
Despite the difficulties of studying an uncommon manifestation of a rare syndrome, our
findings suggest an excess occurrence of early-onset gastric cancer in TP53 mutation-
positive families. The results are similar to our other observations on colorectal cancer in
LFS21, and may have implications for diagnostic and preventive interventions in selected
families. Due to the broad array of cancers associated with LFS and the lack of effective
screening modalities for most LFS-related cancers, such as sarcomas and brain tumors, the
measures aimed at early cancer detection are limited. The only available guidelines for
cancer screening in TP53 carriers are from the NCCN and suggest that screening for breast
and colorectal cancers is advisable 22. Our group has reported a pilot study evaluating the
role of whole-body PET (positron emission tomography)/CT (computerized tomography)
scan in 15 LFS families.40 In that study a tumor of the gastro-esophageal junction was
detected by scan and confirmed with esophago-gastro-duodenoscopy (EGD). Given the
colonoscopy recommendations for surveillance of colorectal cancer, the addition of periodic
screening with EGD in germline TP53 carriers may be reasonable to consider, particularly in
LFS families in which at least one member has gastric cancer. The early age at diagnosis in
comparison to the general population suggests that surveillance may need to begin in young
adults. Nevertheless, we need to consider the data showing that upper GI endoscopies were
frequently normal in patients with diffuse gastric cancer which was eventually diagnosed
after prophylactic surgery41. More data are needed to establish the effectiveness and
appropriate intervals for screening with EGD in TP53 carriers, in addition to targeted
interventions based on individual family history.
In summary, although it is an uncommon manifestation of LFS, early–onset gastric cancer
appears to be a component of the spectrum of tumors that are associated with this familial
syndrome. Further studies are needed to determine the role of EGD as well as other cancer
detection measures among individuals with TP53 germline mutations.
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Distribution of Gastric Cancer by Age in DFCI/ NCI LFS registry and the SEER database
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tFigure 2.
Pedigree plots of 3 families (Families 4, 8 and 11) with multiple cases of early onset gastric
cancers and a known TP53 mutation. The circles represent females while the squares
represent males. Open symbols indicate no neoplasm and filled symbols represent those with
cancer; crossed symbols indicate deceased individuals. Arrows indicate probands, allpositive
for a TP53 mutation. STO/GEJ, stomach/gastroesophageal junction cancer; BR, breast
cancer; SS, soft-tissue sarcomas; OS, osteosarcoma; CNS, central nervous system cancer;
CO, colon cancer; PAN, pancreatic cancer; LG, lung cancer; ENDO, endometrial cancer;
KID, kidney tumor; PR, prostate cancer; ACC, adrenal cortical cancer; TC, thyroid cancer.
Numbers after the symbols for the type of cancer indicate age at death or age at diagnosis.
The pedigrees have been de-identified to protect confidentiality. The pedigree of family 8
has been previously published42.
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Example of intestinal type moderately differentiated (A) and diffuse type gastric
adenocarcinoma (B) observed in our cohort
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Table 1
Gastric cancer in hereditary cancer syndromes.
Syndromes Gene Involved Gastric Cancer Risk References
Hereditary Diffuse Gastric Cancer CDH1 67%-83% Pharoa et al39
Syndrome (HDGC) Kaurah et al8
Hereditary Non Polyposis Colorectal MLH1, MSH2, 2%-30% . Koornstra et al40
Cancer (HNPCC) MSH6, PMS2
Peutz-Jeghers Syndrome (PJS) STK11 29% van Lier et al 41
Hereditary Breast/Ovarian Cancer BRCA1 5.5% Thompson et al42
Brose et al43
Syndrome (HBOC) BRCA2 2.6% Breast Cancer Linkage Consortium44
Easton et al45
Familial Adenomatous Polyposis (FAP) APC 2.1%-4.2%* Park et al46
Iwama et al47
Juvenile Polyposis Syndrome (JPS)^ SMAD4, BMPR1A N/A -
Li-Fraumeni Syndrome (LFS)^ TP53 N/A -
*
This increased risk is for the Korean and Japanese populations. In other ethnicities the risk is the same as the general population.
^
The estimate of the gastric cancer risk has not been calculated for these conditions
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